openPR Logo
Press release

Keratoconus Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix

04-24-2024 08:10 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Keratoconus Market to Exhibit Rapid Growth Rate During

DelveInsight's "Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Keratoconus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Keratoconus Market Forecast
https://www.delveinsight.com/sample-request/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Keratoconus Market Report:
• The Keratoconus market size was valued approximately USD 3 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2021, the expected total diagnosed prevalent population of Keratoconus throughout the seven primary markets was 1,818,900
• In the United States, it was discovered that there were approximately 743,000 diagnosed cases of keratoconus in 2021.
• In Japan, there were around 257,600 diagnosed cases of Keratoconus in 2021.
• NORD estimates that the prevalence of keratoconus in the general population in the United States in 2019 was 54.5 per 100,000 people, or roughly 1 in 2,000 people. People who have a family history of keratoconus are more likely to get the illness than members of the general public.
• In August 2022, iVeena entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 for KC.
• In September 2022, CXL Opthhalmics presented its Phase II data and according to the data 80% of patients maintained or improved corrected distance visual acuity 12 months post-operation and 89%of patients 21 years or younger showed stable or improved vision at 12 months.
• Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others
• Key Keratoconus Therapies: Riboflavin 5'-Phosphate, IVMED-80, Dextenza, and others
• The Keratoconus epidemiology based on gender analyzed that Keratoconus affects both males and females equally
• The Intacs Device from Price Vision Group and the Photrexa and Photrexa Viscousa from Avedro are among the US FDA-approved treatments for KC. Intacs are ocular medical inserts intended to reduce or eliminate myopia and astigmatism in patients with KC, whereas Photrexa and Photrexa Viscous are photoenhancers recommended for use with the KXL System in corneal collagen cross-linking for the treatment of patients with progressive KC.
• The Keratoconus market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Keratoconus pipeline products will significantly revolutionize the Keratoconus market dynamics.

Keratoconus Overview
The eye (ocular) condition known as keratoconus (KC) is characterized by the cornea's gradual thinning and alterations in form. The cornea is the outermost layer of the eye that is clear and thin. It often has a dome shape. A cone-shaped protrusion forms toward the center of the cornea in the places where the cornea is thinning the fastest due to slowly progressive corneal thinning.

Get a Free sample for the Keratoconus Market Report:
https://www.delveinsight.com/report-store/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Keratoconus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Keratoconus Epidemiology Segmentation:
The Keratoconus market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Keratoconus
• Prevalent Cases of Keratoconus by severity
• Gender-specific Prevalence of Keratoconus
• Diagnosed Cases of Episodic and Chronic Keratoconus

Download the report to understand which factors are driving Keratoconus epidemiology trends @ Keratoconus Epidemiology Forecast
https://www.delveinsight.com/sample-request/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Keratoconus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Keratoconus market or expected to get launched during the study period. The analysis covers Keratoconus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Keratoconus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Keratoconus Therapies and Key Companies
• Riboflavin 5'-Phosphate: Glaukos Corporation
• IVMED-80: iVeena Delivery Systems
• Dextenza: Ocular Therapeutix, Inc.

Discover more about therapies set to grab major Keratoconus market share @ Keratoconus Treatment Market
https://www.delveinsight.com/sample-request/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Keratoconus Market Strengths
• Environmental factors contribute to the wide variation in prevalence. Geographical locations with plenty of sunshine and hot weather have a higher prevalence than locations with colder climates and less sunlight

Keratoconus Market Opportunities
• There is limited approved therapy for Keratoconus, which opens up a huge platform of new therapies to boon the market.

Scope of the Keratoconus Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others
• Key Keratoconus Therapies: Riboflavin 5'-Phosphate, IVMED-80, Dextenza, and others
• Keratoconus Therapeutic Assessment: Keratoconus current marketed and Keratoconus emerging therapies
• Keratoconus Market Dynamics: Keratoconus market drivers and Keratoconus market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Keratoconus Unmet Needs, KOL's views, Analyst's views, Keratoconus Market Access and Reimbursement

To know more about Keratoconus companies working in the treatment market, visit @ Keratoconus Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Keratoconus Market Report Introduction
2. Executive Summary for Keratoconus
3. SWOT analysis of Keratoconus
4. Keratoconus Patient Share (%) Overview at a Glance
5. Keratoconus Market Overview at a Glance
6. Keratoconus Disease Background and Overview
7. Keratoconus Epidemiology and Patient Population
8. Country-Specific Patient Population of Keratoconus
9. Keratoconus Current Treatment and Medical Practices
10. Keratoconus Unmet Needs
11. Keratoconus Emerging Therapies
12. Keratoconus Market Outlook
13. Country-Wise Keratoconus Market Analysis (2019-2032)
14. Keratoconus Market Access and Reimbursement of Therapies
15. Keratoconus Market Drivers
16. Keratoconus Market Barriers
17. Keratoconus Appendix
18. Keratoconus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Keratoconus Pipeline https://www.delveinsight.com/report-store/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Keratoconus Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Keratoconus market. A detailed picture of the Keratoconus pipeline landscape is provided, which includes the disease overview and Keratoconus treatment guidelines.
Keratoconus Epidemiology https://www.delveinsight.com/report-store/keratoconus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Keratoconus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Keratoconus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Keratoconus Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix here

News-ID: 3475426 • Views:

More Releases from DelveInsight Business Research

Vascular Dementia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP
Vascular Dementia Market Report 2032: Epidemiology Data, Pipeline Therapies, Lat …
DelveInsight's "Vascular Dementia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vascular Dementia, historical and forecasted epidemiology as well as the Vascular Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Vascular Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vascular Dementia Market Forecast https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Limb Girdle Muscular Dystrophy Pipeline Assessment, 2024: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Ph
Limb Girdle Muscular Dystrophy Pipeline Assessment, 2024: FDA, EMA, and PMDA App …
Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Limb Girdle Muscular Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market. The Limb Girdle Muscular Dystrophy
RIPK1 Inhibitor Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Sanofi, Genfleet Therapeutics, Rigel Pharma, GlaxoSmithKline, AbbVie, Sanofi, Voronoi, Boston Pharm
RIPK1 Inhibitor Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approv …
RIPK1 Inhibitor pipeline constitutes 10+ key companies continuously working towards developing 12+ RIPK1 Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "RIPK1 Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market. The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the
Atypical Teratoid Rhabdoid Tumors Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuti
Atypical Teratoid Rhabdoid Tumors Pipeline Report, 2024 Updates : In-depth Analy …
Atypical Teratoid Rhabdoid Tumors pipeline constitutes 5+ key companies continuously working towards developing 5+ Atypical Teratoid Rhabdoid Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Atypical Teratoid Rhabdoid Tumors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atypical Teratoid Rhabdoid Tumors Market. The Atypical Teratoid Rhabdoid Tumors

All 5 Releases


More Releases for Keratoconus

Keratoconus Market Trends, Key Players Insight, Epidemiology and Market Forecast …
Keratoconus (KC) Market Insights, Epidemiology and Market Forecast, 2030 report delivers an in-depth understanding of the Keratoconus (KC), historical and forecasted epidemiology as well as the Keratoconus (KC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Keratoconus (KC) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Keratoconus (KC) market size from
Keratoconus Treatment Market is Estimated to Flourish by 2027
Keratoconus is considered to be a progressive eye disorder in which the cornea, which is normally round in shape, thins, and starts bulging into a cone-like shape. This cone shape causes the light entering the eye to deflect on its way to the light-sensitive retina, thereby resulting into distorted vision. Weakening of corneal tissue which results into keratoconus can be because of enzymes imbalance within the cornea. Report Overview @ https://www.transparencymarketresearch.com/keratoconus-treatment-market.html This
Keratoconus Treatment Market Bausch & Lomb Incorporated, CIBA VISION, CooperVisi …
Market research future has a half cooked research report on Global Keratoconus Treatment Market. The market for keratoconus treatment was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%. The Global Keratoconus Treatment Market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future. Approximately 3 million people are affected
Keratoconus Treatment Market is expected to reach USD 427.5 million by 2023
Market research future has a half cooked research report on Global Keratoconus Treatment Market. The Global Keratoconus Treatment Market is growing continuously and expected to grow at a CAGR of 4.1% from 2017 to 2023 The market for keratoconus treatment was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%. The Global Keratoconus Treatment Market has been evaluated
Keratoconus Treatment Market 2018 Top Key Player - Lomb Incorporated, CIBA Visio …
The Global Keratoconus Treatment Market was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%. Approximately 3 million people are affected by this disease across the globe. Advanced diagnostic and treatment options are key drivers for this market. Increasing awareness of the disease, increasing funding for R&D and growing demand from emerging regions such as Asia are
Keratoconus Treatment Global Market 2017: Key Players – CooperVision, HOYA Vis …
The Global Keratoconus Treatment Market Reports has been segmented on the basis of type which comprises of forme fruste keratoconus, corneal hydrops, keratoglobus, pellucid marginal degeneration, posterior keratoconus, and others. On the basis of diagnosis, the market is segmented into computerized corneal mapping, keratometry, slit-lamp examination, refraction test, and others. Slit-lamp examination includes tonometry, vision testing, and others. GET SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/3861 . On the basis of treatments, the market has been